Become a donor or member and support our work to advance access to medicines. For everyone. Everywhere
Since its establishment, Health Action International (HAI) has carried out much-needed research as part of our projects and prorgammes, generating an extensive evidence base of knowledge. The following is a non-exhaustive collection of journal articles and other publications on which HAI has led or contributed across its working areas throughout the years.
(NB: the links below lead to external sites)
1. Ooms GI, Usman MA, Reed T, van den Ham HA, Mantel-Teeuwisse AK. The impact of scheduling ketamine as an internationally controlled substance on anaesthesia care in Sub-Saharan Africa: a case study and key informant interviews. BMC Health Serv Res. 2024 May 7;24(1):598. doi: 10.1186/s12913-024-11040-w. PMID: 38715038; PMCID: PMC11077710.
2. Jacobs TG, Okemo D, Ssebagereka A, Mwehonge K, Njuguna EM, Burger DM, Colbers A, Suleman F, Mantel-Teeuwisse AK, Ooms GI. Availability and stock-outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda. HIV Med. 2024 Jul;25(7):805-816. doi: 10.1111/hiv.13635. Epub 2024 Mar 18. PMID: 38499513.
3. Ooms GI, van Oirschot J, de Kant D, van den Ham HA, Mantel-Teeuwisse AK, Reed T. Barriers to accessing internationally controlled essential medicines in sub-saharan Africa: A scoping review. Int J Drug Policy. 2023 Aug;118:104078. doi: 10.1016/j.drugpo.2023.104078. Epub 2023 Jun 3. PMID: 37276779.
4. Ten Have NJ, Ooms GI, Waldmann B, Reed T. Barriers and enablers of community engagement practices for the prevention of snakebite envenoming in South Asia: A qualitative exploratory study. Toxicon X. 2022 Dec 5;17:100144. doi: 10.1016/j.toxcx.2022.100144. PMID: 36561733; PMCID: PMC9764250.
5. Ooms GI, van Oirschot J, Okemo D, Reed T, van den Ham HA, Mantel-Teeuwisse AK. Healthcare workers’ perspectives on access to sexual and reproductive health services in the public, private and private not-for-profit sectors: insights from Kenya, Tanzania, Uganda and Zambia. BMC Health Serv Res. 2022 Jul 6;22(1):873. doi: 10.1186/s12913-022-08249-y. PMID: 35794551; PMCID: PMC9261038.
6. Ooms GI, van Oirschot J, Okemo D, Waldmann B, Erulu E, Mantel-Teeuwisse AK, van den Ham HA, Reed T. Availability, affordability and stock-outs of commodities for the treatment of snakebite in Kenya. PLoS Negl Trop Dis. 2021 Aug 16;15(8):e0009702. doi: 10.1371/journal.pntd.0009702. PMID: 34398889; PMCID: PMC8389522.
7. van Oirschot J, Ooms GI, Waldmann B, Kadam P. Snakebite incidents, prevention and care during COVID-19: Global key-informant experiences. Toxicon X. 2021 Jul 15;9-10:100075. doi: 10.1016/j.toxcx.2021.100075. PMID: 34386765; PMCID: PMC8342778.
8. Ooms GI, van Oirschot J, Waldmann B, Okemo D, Mantel-Teeuwisse AK, van den Ham HA, Reed T. The Burden of Snakebite in Rural Communities in Kenya: A Household Survey. Am J Trop Med Hyg. 2021 Jul 19;105(3):828-836. doi: 10.4269/ajtmh.21-0266. PMID: 34280130; PMCID: PMC8592359.
9. van Oirschot J, Ooms GI, Okemo DJ, Waldmann B, Reed T. An exploratory focus group study on experiences with snakebites: health-seeking behaviour and challenges in rural communities of Kenya. Trans R Soc Trop Med Hyg. 2021 Jun 2;115(6):613-618. doi: 10.1093/trstmh/trab059. PMID: 33836536.
10. Kibira D, Ooms GI, van den Ham HA, Namugambe JS, Reed T, Leufkens HG, Mantel-Teeuwisse A. Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: a cross-sectional assessment of availability, prices and affordability. BMJ Open. 2021 Jan 7;11(1):e042948. doi: 10.1136/bmjopen-2020-042948. PMID: 33414148; PMCID: PMC7797249.
11. Ooms GI, van Oirschot J, Waldmann B, von Bernus S, van den Ham HA, Mantel-Teeuwisse AK, Reed T. The Current State of Snakebite Care in Kenya, Uganda, and Zambia: Healthcare Workers’ Perspectives and Knowledge, and Health Facilities’ Treatment Capacity. Am J Trop Med Hyg. 2020 Nov 23;104(2):774-782. doi: 10.4269/ajtmh.20-1078. PMID: 33236717; PMCID: PMC7866361.
12. Ooms GI, Kibira D, Reed T, van den Ham HA, Mantel-Teeuwisse AK, Buckland-Merrett G. Access to sexual and reproductive health commodities in East and Southern Africa: a cross-country comparison of availability, affordability and stock-outs in Kenya, Tanzania, Uganda and Zambia. BMC Public Health. 2020 Jul 3;20(1):1053. doi: 10.1186/s12889-020-09155-w. PMID: 32620159; PMCID: PMC7333276.
13. Ooms GI, Klatser P, van den Ham HA, Reed T. Barriers to Accessing Internationally Controlled Essential Medicines in Uganda: A Qualitative Study. J Pain Symptom Manage. 2019 Nov;58(5):835-843.e1. doi: 10.1016/j.jpainsymman.2019.07.002. Epub 2019 Jul 11. PMID: 31302261.
14. Schurer JM, Murara E, van Oirschot J, Ooms G. Antivenom for sale? Availability and affordability of snakebite medicines across public and private health facilities in Rwanda. Toxicon. 2023 Oct;234:107292. doi: 10.1016/j.toxicon.2023.107292. Epub 2023 Sep 19. PMID: 37734455.
15. Kibira D, Boydell V, Mworeko L, Kiarie J. Considerations for social accountability in the expansion of self-care for sexual and reproductive health and rights. Sex Reprod Health Matters. 2021;29(3):2083812. doi: 10.1080/26410397.2022.2083812. PMID: 35975672; PMCID: PMC9387307.
16. Kibira D, Asiimwe C, Muwonge M, van den Ham HA, Reed T, Leufkens HG, Mantel-Teeuwisse AK. Donor Commitments and Disbursements for Sexual and Reproductive Health Aid in Kenya, Tanzania, Uganda and Zambia. Front Public Health. 2021 Apr 20;9:645499. doi: 10.3389/fpubh.2021.645499. PMID: 33959580; PMCID: PMC8093629.
17. Perehudoff K, Kibira D, Wuyts E, Pericas C, Omwoha J, van den Ham HA, Mantel-Teeuwisse AK, Michielsen K. A comparative human rights analysis of laws and policies for adolescent contraception in Uganda and Kenya. Reprod Health. 2022 Feb 7;19(1):37. doi: 10.1186/s12978-021-01303-8. PMID: 35130932; PMCID: PMC8822716.
18. Kibira D, Ssebagereka A, van den Ham HA, Opigo J, Katamba H, Seru M, Reed T, Leufkens HG, Mantel-Teeuwisse AK. Trends in access to anti-malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first-line anti-malarials and diagnostics between 2007 and 2018. Malar J. 2021 Mar 10;20(1):142. doi: 10.1186/s12936-021-03680-8. PMID: 33691704; PMCID: PMC7944888.
19. Kibira D, Kitutu FE, Merrett GB, Mantel-Teeuwisse AK. Availability, prices and affordability of UN Commission’s lifesaving medicines for reproductive and maternal health in Uganda. J Pharm Policy Pract. 2017 Nov 15;10:35. doi: 10.1186/s40545-017-0123-9. PMID: 29163976; PMCID: PMC5686951.
20. Beran D, Abidha C, Adler A, de Beaufort C, Lepeska M, Levitt N, Pfiester E, Zafra-Tanaka JH, Gale EA. Teplizumab approval for type 1 diabetes in the USA. Lancet Diabetes Endocrinol. 2023 Feb;11(2):78-80. doi: 10.1016/S2213-8587(22)00384-9. Epub 2023 Jan 6. PMID: 36623522.
21. Safary E, Beran D, Vetter B, Lepeska M, Abdraimova A, Dunganova A, Besançon S, Lazo-Porras M, Portocarrero Mazanett J, Pérez-León S, Maixenchs M, Nchimbi H, Ramaiya K, Munishi C, Martínez-Pérez GZ. User requirements for non-invasive and minimally invasive glucose self-monitoring devices in low-income and middle-income countries: a qualitative study in Kyrgyzstan, Mali, Peru and Tanzania. BMJ Open. 2024 Feb 17;14(2):e076685. doi: 10.1136/bmjopen-2023-076685. PMID: 38367964; PMCID: PMC10875487.
22. Potet J, Beran D, Ray N, Alcoba G, Habib AG, Iliyasu G, Waldmann B, Ralph R, Faiz MA, Monteiro WM, de Almeida Gonçalves Sachett J, di Fabio JL, Cortés MLÁ, Brown NI, Williams DJ. Access to antivenoms in the developing world: A multidisciplinary analysis. Toxicon X. 2021 Oct 26;12:100086. doi: 10.1016/j.toxcx.2021.100086. PMID: 34786555; PMCID: PMC8578041.
23. Buckland-Merrett GL, Kilkenny C, Reed T. Civil society engagement in multi-stakeholder dialogue: a qualitative study exploring the opinions and perceptions of MeTA members. J Pharm Policy Pract. 2017 Jan 6;10:5. doi: 10.1186/s40545-016-0096-0. PMID: 28070340; PMCID: PMC5217617.
24. ‘t Hoen E, Meyer S, Durisch P, Bannenberg W, Perehudoff K, Reed T, Barber MJ. Improving affordability of new Essential Cancer Medicines. Lancet Oncol. 2019 Aug;20(8):1052-1054. doi: 10.1016/S1470-2045(19)30459-0. Epub 2019 Jul 11. PMID: 31303433.
25. Kedia T, Barnett-Vanes A, Jarvis J, Ragins K, Long C, Owaseye O, Jamnejad M, Young R, Reed T. Equitable access to global health internships: a documentary short. Lancet Glob Health. 2018 Feb;6(2):e145. doi: 10.1016/S2214-109X(17)30499-0. PMID: 29389537.
26. Beran D, Ewen M, Chappuis F, Reed T, Hogerzeil H. Pharmaceutical industry, non-communicable diseases and partnerships: More questions than answers. J Glob Health. 2017 Dec;7(2):020301. doi: 10.7189/jogh.07.020301. PMID: 28959435; PMCID: PMC5804034.
27. Vitry A, Lexchin J, Sasich L, Dupin-Spriet T, Reed T, Bertele V, Garattini S, Toop L, Hurley E. Provision of information on regulatory authorities’ websites. Intern Med J. 2008 Jul;38(7):559-67. doi: 10.1111/j.1445-5994.2007.01588.x. Epub 2008 Mar 11. PMID: 18336542.
28. Abraham J, Reed T. Reshaping the carcinogenic risk assessment of medicines: international harmonisation for drug safety, industry/regulator efficiency or both? Soc Sci Med. 2003 Jul;57(2):195-204. doi: 10.1016/s0277-9536(02)00339-8. PMID: 12765701.
29. Abraham J, Reed T. Progress, innovation and regulatory science in drug development: the politics of international standard-setting. Soc Stud Sci. 2002 Jun;32(3):337-69. doi: 10.1177/0306312702032003001. PMID: 12269340.
30. Abraham, J., & Reed, T. (2001). Trading risks for markets: The international harmonisation of pharmaceuticals regulation. Health, Risk & Society, 3(1), 113–128. https://doi.org/10.1080/713670172
31. Abraham J, Sheppard J, Reed T. Rethinking transparency and accountability in medicines regulation in the United Kingdom. BMJ. 1999 Jan 2;318(7175):46-7. doi: 10.1136/bmj.318.7175.46. PMID: 9872891; PMCID: PMC1114540.
32. Vidal J, Di Fabio YJL. Judicial recourse and access to health technologies: opportunities and risks. Rev Panam Salud Publica. 2017 Dec 5;41:e137. Portuguese. doi: 10.26633/RPSP.2017.137. PMID: 31384265; PMCID: PMC6645191.
33. World Health Organization. (2003). IPR, innovation, human rights and access to drugs : an annotated bibliography / Germán Velásquez, Jaume Vidal, 3rd ed. World Health Organization.
34. Hogerzeil HV, Samson M, Casanovas JV, Rahmani-Ocora L. Is access to essential medicines as part of the fulfilment of the right to health enforceable through the courts? Lancet. 2006 Jul 22;368(9532):305-11. doi: 10.1016/S0140-6736(06)69076-4. PMID: 16860700.
35. García, B.M., Di Fabio, J.L. and Vidal, J. (2015) Patentes y algo más: El Acceso a Los Medicamentos Biotecnológicos, Research Gate. Available at: https://www.researchgate.net/publication/339149464_Patentes_y_algo_mas_el_acceso_a_los_medicamentos_biotecnologicos
36. García Delgado B, Di Fabio JL, Vidal Casanovas J, Fitzgerald J, Silva AP. Salud pública y propiedad intelectual en Cuba: mapa conceptual [Public health and intellectual property in Cuba: a conceptual map]. Rev Panam Salud Publica. 2015 Nov;38(5):355-61. Spanish. PMID: 26837520.
37. García Delgado B, Di Fabio JL, Vidal Casanovas J. Mapa conceptual sobre salud pública y propiedad intelectual en Cuba: actualización 2020 [Conceptual map of public health and intellectual property in Cuba: 2020 updateMapa conceitual sobre saúde pública e propriedade intelectual em Cuba: atualização de 2020]. Rev Panam Salud Publica. 2020 Aug 6;44:e76. Spanish. doi: 10.26633/RPSP.2020.76. PMID: 32774347; PMCID: PMC7406125.
38. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O, Leowski J, Ewen M. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007 Apr;85(4):279-88. doi: 10.2471/blt.06.033647. PMID: 17546309; PMCID: PMC2636320.
39. Kotwani A, Ewen M, Dey D, Iyer S, Lakshmi PK, Patel A, Raman K, Singhal GL, Thawani V, Tripathi S, Laing R. Prices & availability of common medicines at six sites in India using a standard methodology. Indian J Med Res. 2007 May;125(5):645-54. PMID: 17642500.
40. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009 Jan 17;373(9659):240-9. doi: 10.1016/S0140-6736(08)61762-6. Epub 2008 Nov 29. Erratum in: Lancet. 2009 Feb 21;373(9664):632. PMID: 19042012.
41. Cameron, A. et al. (2009) ‘Better measures of affordability required – authors’ reply’, The Lancet, 373(9669), pp. 1081–1082. doi:10.1016/s0140-6736(09)60650-4.
42. Madden JM, Meza E, Ewen M, Laing RO, Stephens P, Ross-Degnan D. Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey methodology. Rev Panam Salud Publica. 2010 Apr;27(4):291-9. doi: 10.1590/s1020-49892010000400008. Erratum in: Rev Panam Salud Publica. 2010 Jun;27(6):472. PMID: 20512232.
43. van Mourik MS, Cameron A, Ewen M, Laing RO. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord. 2010 Jun 9;10:25. doi: 10.1186/1471-2261-10-25. PMID: 20534118; PMCID: PMC2898673.
44. Niëns LM, Cameron A, Van de Poel E, Ewen M, Brouwer WB, Laing R. Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. PLoS Med. 2010 Aug 31;7(8):e1000333. doi: 10.1371/journal.pmed.1000333. PMID: 20824175; PMCID: PMC2930876.
45. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HG, Laing RO. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ. 2011 Jun 1;89(6):412-21. doi: 10.2471/BLT.10.084327. Epub 2011 Mar 14. PMID: 21673857; PMCID: PMC3099556.
46. Niëns LM, Van de Poel E, Cameron A, Ewen M, Laing R, Brouwer WB. Practical measurement of affordability: an application to medicines. Bull World Health Organ. 2012 Mar 1;90(3):219-27. doi: 10.2471/BLT.10.084087. Epub 2012 Jan 27. PMID: 22461717; PMCID: PMC3314216.
47. Beran D; Besançon S; Ewen M; Gale EAM; Lazo-Porras M ;Lepeska M; Lipska K; Zafra-Tanaka J; Zhaparova A; Yudkin JS; (2012) Diabetes and the WHO model list of essential medicines, The lancet. Diabetes & endocrinology. Available at: https://pubmed.ncbi.nlm.nih.gov/34919864/.
48. Bazargani YT, Ewen M, de Boer A, Leufkens HG, Mantel-Teeuwisse AK. Essential medicines are more available than other medicines around the globe. PLoS One. 2014 Feb 12;9(2):e87576. doi: 10.1371/journal.pone.0087576. PMID: 24533058; PMCID: PMC3922716.
49. Ewen M, Al Sakit M, Saadeh R, Laing R, Vialle-Valentin C, Seita A, Bunders J. Comparative assessment of medicine procurement prices in the United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA). J Pharm Policy Pract. 2014 Oct 21;7(1):13. doi: 10.1186/2052-3211-7-13. PMID: 25379183; PMCID: PMC4210580.
50. Kaplan W, Laing R, Ewen M, Beran D. Insulin patents and market exclusivities: unresolved issues. Lancet Diabetes Endocrinol. 2016 Feb;4(2):98. doi: 10.1016/S2213-8587(15)00496-9. PMID: 26825233.
51. Beran D, Ewen M, Laing R. Constraints and challenges in access to insulin: a global perspective. Lancet Diabetes Endocrinol. 2016 Mar;4(3):275-285. doi: 10.1016/S2213-8587(15)00521-5. Epub 2016 Feb 6. PMID: 26857998.
52. Sharma A, Rorden L, Ewen M, Laing R. Evaluating availability and price of essential medicines in Boston area (Massachusetts, USA) using WHO/HAI methodology. J Pharm Policy Pract. 2016 Apr 5;9:12. doi: 10.1186/s40545-016-0059-5. PMID: 27054040; PMCID: PMC4822245.
53. Beran D, Ewen M, Laing R. Insulin in 2016: Challenge and constraints to access. Diabetes Res Clin Pract. 2016 Jul;117:119-21. doi: 10.1016/j.diabres.2016.06.001. PMID: 27329030.
54. Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, Gyansa-Lutterodt M, Jing S, Luiza VL, Mbindyo RM, Möller H, Moucheraud C, Pécoul B, Rägo L, Rashidian A, Ross-Degnan D, Stephens PN, Teerawattananon Y, ‘t Hoen EF, Wagner AK, Yadav P, Reich MR. Essential medicines for universal health coverage. Lancet. 2017 Jan 28;389(10067):403-476. doi: 10.1016/S0140-6736(16)31599-9. Epub 2016 Nov 8. PMID: 27832874; PMCID: PMC7159295.
55. Ewen M, Kaplan W, Gedif T, Justin-Temu M, Vialle-Valentin C, Mirza Z, Regeer B, Zweekhorst M, Laing R. Prices and availability of locally produced and imported medicines in Ethiopia and Tanzania. J Pharm Policy Pract. 2017 Jan 16;10:7. doi: 10.1186/s40545-016-0095-1. PMID: 28116107; PMCID: PMC5242052.
56. Ewen M, Zweekhorst M, Regeer B, Laing R. Baseline assessment of WHO’s target for both availability and affordability of essential medicines to treat non-communicable diseases. PLoS One. 2017 Feb 7;12(2):e0171284. doi: 10.1371/journal.pone.0171284. PMID: 28170413; PMCID: PMC5295694.
57. Perrin C, Ewen M, Beran D. The role of biosimilar manufacturers in improving access to insulin globally. Lancet Diabetes Endocrinol. 2017 Aug;5(8):578. doi: 10.1016/S2213-8587(17)30218-8. Epub 2017 Jun 16. PMID: 28629907.
58. Liu C, Zhang X, Liu C, Ewen M, Zhang Z, Liu G. Insulin prices, availability and affordability: a cross-sectional survey of pharmacies in Hubei Province, China. BMC Health Serv Res. 2017 Aug 24;17(1):597. doi: 10.1186/s12913-017-2553-0. PMID: 28836974; PMCID: PMC5571633.
59. Beran D, Ewen M, Lipska K, Hirsch IB, Yudkin JS. Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment. Curr Diab Rep. 2018 Jun 16;18(8):48. doi: 10.1007/s11892-018-1019-z. PMID: 29907884.
60. Beran D, Laing RO, Kaplan W, Knox R, Sharma A, Wirtz VJ, Frye J, Ewen M. A perspective on global access to insulin: a descriptive study of the market, trade flows and prices. Diabet Med. 2019 Jun;36(6):726-733. doi: 10.1111/dme.13947. Epub 2019 Apr 7. PMID: 30888075; PMCID: PMC6593686.
61. Ewen M, Joosse HJ, Beran D, Laing R. Insulin prices, availability and affordability in 13 low-income and middle-income countries. BMJ Glob Health. 2019 Jun 11;4(3):e001410. doi: 10.1136/bmjgh-2019-001410. PMID: 31263585; PMCID: PMC6570978.
62. Ball D, Ewen M, Laing R, Beran D. Insulin price components: case studies in six low/middle-income countries. BMJ Glob Health. 2019 Sep 11;4(5):e001705. doi: 10.1136/bmjgh-2019-001705. PMID: 31565414; PMCID: PMC6747921.
63. Tenorio-Mucha J, Lazo-Porras M, Hidalgo-Padilla L, Beran D, Ewen M. Precios, disponibilidad y asequibilidad de insulina en farmacias públicas y privadas en Perú Rev Panam Salud Publica. 2019 Oct 31;43:e85. Spanish. doi: 10.26633/RPSP.2019.85. PMID: 31768180; PMCID: PMC6822689.
64. Khanal S, Veerman L, Ewen M, Nissen L, Hollingworth S. Availability, Price, and Affordability of Essential Medicines to Manage Noncommunicable Diseases: A National Survey From Nepal. Inquiry. 2019 Jan-Dec;56:46958019887572. doi: 10.1177/0046958019887572. PMID: 31823665; PMCID: PMC6906349.
65. Moye-Holz D, Ewen M, Dreser A, Bautista-Arredondo S, Soria-Saucedo R, van Dijk JP, Reijneveld SA, Hogerzeil HV. Availability, prices, and affordability of selected essential cancer medicines in a middle-income country – the case of Mexico. BMC Health Serv Res. 2020 May 14;20(1):424. doi: 10.1186/s12913-020-05167-9. PMID: 32410676; PMCID: PMC7222474.
66. Beran D, Colagiuri S, Ernoult N, Ewen M, Fleury C, Lepeska M, Londeix P, Pfiester E, Yudkin JS, Besançon S. Failing to address access to insulin in its centenary year would be a catastrophic moral failure. Lancet Diabetes Endocrinol. 2021 Apr;9(4):194-196. doi: 10.1016/S2213-8587(21)00048-6. Epub 2021 Mar 3. PMID: 33675694.
67. Lepeska, M., Beran, D. and Ewen, M. (2021) ‘Access to insulin: A comparison between low‐ and middle‐income countries and the United Kingdom’, Practical Diabetes, 38(4), pp. 13–16. doi:10.1002/pdi.2345.
68. Beran D, Besançon S, Ewen M, Gale EAM, Lazo-Porras M, Lepeska M, Lipska K, Zafra-Tanaka J, Zhaparova A, Yudkin JS. Diabetes and the WHO Model List of Essential Medicines. Lancet Diabetes Endocrinol. 2022 Jan;10(1):17-18. doi: 10.1016/S2213-8587(21)00323-5. PMID: 34919864.
69. Abdraimova A, Besançon S, Portocarrero J, Ramaiya K, Dunganova A, Ewen M, Hogerzeil H, Lazo-Porras M, Laing R, Lepeska M, Nchimbi H, Sidibé A, Swai A, Tenorio-Mucha J, Yudkin JS, Zafra-Tanaka JH, Zurdinova A, Beran D. Management of type 1 diabetes in low- and middle-income countries: Comparative health system assessments in Kyrgyzstan, Mali, Peru and Tanzania. Diabet Med. 2022 Aug;39(8):e14891. doi: 10.1111/dme.14891. Epub 2022 Jun 6. PMID: 35621029; PMCID: PMC9543552.
70. Tenorio-Mucha J, Lazo-Porras M, Zafra J, Ewen M, Beran D. Using government data to understand the use and availability of medicines for hypertension and diabetes: lessons from Peru. J Pharm Policy Pract. 2022 Nov 18;15(1):86. doi: 10.1186/s40545-022-00481-5. PMID: 36401297; PMCID: PMC9675072.